The Paris team advised the banks syndicate composed of Van Lanschot Kempen N.V. and Swiss Life Banque Privée on the approximately €105 million fundraising of Transgene. The transaction was carried out through the issuance of new shares to specialized investors via private placement through an accelerated book building and to retail investors via the PrimaryBid platform, at a price of €1.02 per share. Concurrently, Transgene carried out a capital increase reserved for TSGH for approximately €40 million by way of set-off.
Investors from Europe and France, specializing in the healthcare sector, participated in the fundraising alongside the Company's main historical shareholders (Institut Mérieux and the Dassault Group).
This fundraising will enable the acceleration of the development of the myvac program, Transgene's platform for individualized therapeutic cancer vaccines, and extend its financial visibility until early 2028.
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
The Goodwin team included Guilhem Richard and Shanna Kim on the French law aspects, as well as Edwin O'Connor on the U.S. law aspects.